Surgically implanted endovascular, microaxial left ventricular assist device : A single institution study
© 2024 The Authors..
Objective: The Impella 5.5 (Abiomed, Inc), a surgically implanted endovascular microaxial left ventricular assist device, is increasingly used worldwide and there have been more than 10,000 implants. The purpose of this study is to describe a large-volume, single-center experience with the use of the Impella 5.5.
Methods: Data were obtained retrospectively from patients supported with the Impella 5.5 implanted at our institution from May 1, 2020, to December 31, 2022. Demographic, operative, and postoperative outcomes for each group are described. Results are reported in median (interquartile range) or n (%). The entire cohort was divided into 5 main groups based on the intention to treat at the time of the Impella 5.5 implantation: (1) patients who had a planned Impella 5.5 implanted at the time of high-risk cardiac surgery; (2) patients with cardiogenic shock; (3) patients bridged to a durable left ventricular assist device; (4) patients bridged to transplant; and (5) patients with postcardiotomy shock who received an unplanned Impella 5.5 implant.
Results: A total of 126 patients were supported with the Impella 5.5. Overall survival to device explant was 76.2%, with 67.5% surviving to discharge. Midterm survival was assessed with a median follow-up time of 318 days and demonstrated an overall survival of 60.3% and a median of 650 days (549-752).
Conclusions: Outcomes after using the Impella 5.5 are variable depending on the indication of use. Patient selection may be of utmost importance and requires further experience with this device to determine who will benefit from insertion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
JTCVS techniques - 23(2024) vom: 14. Feb., Seite 63-71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schumer, Erin M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiogenic shock |
|---|
| Anmerkungen: |
Date Revised 15.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.xjtc.2023.10.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368420957 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368420957 | ||
| 003 | DE-627 | ||
| 005 | 20240215232119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xjtc.2023.10.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM368420957 | ||
| 035 | |a (NLM)38351990 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schumer, Erin M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surgically implanted endovascular, microaxial left ventricular assist device |b A single institution study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Objective: The Impella 5.5 (Abiomed, Inc), a surgically implanted endovascular microaxial left ventricular assist device, is increasingly used worldwide and there have been more than 10,000 implants. The purpose of this study is to describe a large-volume, single-center experience with the use of the Impella 5.5 | ||
| 520 | |a Methods: Data were obtained retrospectively from patients supported with the Impella 5.5 implanted at our institution from May 1, 2020, to December 31, 2022. Demographic, operative, and postoperative outcomes for each group are described. Results are reported in median (interquartile range) or n (%). The entire cohort was divided into 5 main groups based on the intention to treat at the time of the Impella 5.5 implantation: (1) patients who had a planned Impella 5.5 implanted at the time of high-risk cardiac surgery; (2) patients with cardiogenic shock; (3) patients bridged to a durable left ventricular assist device; (4) patients bridged to transplant; and (5) patients with postcardiotomy shock who received an unplanned Impella 5.5 implant | ||
| 520 | |a Results: A total of 126 patients were supported with the Impella 5.5. Overall survival to device explant was 76.2%, with 67.5% surviving to discharge. Midterm survival was assessed with a median follow-up time of 318 days and demonstrated an overall survival of 60.3% and a median of 650 days (549-752) | ||
| 520 | |a Conclusions: Outcomes after using the Impella 5.5 are variable depending on the indication of use. Patient selection may be of utmost importance and requires further experience with this device to determine who will benefit from insertion | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiogenic shock | |
| 650 | 4 | |a temporary mechanical circulatory support | |
| 650 | 4 | |a ventricular assist device | |
| 700 | 1 | |a Bai, Yun Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Kotkar, Kunal D |e verfasserin |4 aut | |
| 700 | 1 | |a Masood, M Faraz |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Akinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Schilling, Joel D |e verfasserin |4 aut | |
| 700 | 1 | |a Ewald, Gregory A |e verfasserin |4 aut | |
| 700 | 1 | |a Damiano, Marci S |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Tsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Damiano, Ralph J |e verfasserin |4 aut | |
| 700 | 1 | |a Pawale, Amit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JTCVS techniques |d 2020 |g 23(2024) vom: 14. Feb., Seite 63-71 |w (DE-627)NLM314117806 |x 2666-2507 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g day:14 |g month:02 |g pages:63-71 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xjtc.2023.10.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |b 14 |c 02 |h 63-71 | ||